Overview

Update
IPO / Stock
Went Public on Jan 31, 2014 / NASDAQ:RARE
Total Equity Funding
$135.1M in 3 Rounds from 6 Investors
Headquarters:
Novato, CA
Description:
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
Founders:
Categories:
Pharmaceutical, Health Care, Biotechnology
Website:
http://www.ultragenyx.com
Social:

Company Details

Update

Ultragenyxâ„¢ develops therapeutics for rare diseases, sometimes referred to as Orphan products. Founded in 2010, the company is led by Emil Kakkis, M.D., Ph.D., former CMO of BioMarin Pharmaceutical. Efficient and effective development strategies are essential for success in the rare disease space, in which information may be incomplete or ambiguous, and few development precedents exist. The management team's experience in selecting and developing products with clear mechanisms of action for untreated rare diseases will help Ultragenyx create life-changing therapeutics by leveraging existing yet undeveloped science for these little-known indications.

Funding Rounds (4) - $200.1M

Update
DateAmount / RoundValuationLead InvestorInvestors
Jun, 2016$65M / Post Ipo Equity2
Dec, 2012$75M / Private Equity6
Jul, 2012$15.1M / Series A1
Jun, 2011$45M / Series A3

Current Team (4)

Update

Board Members and Advisors (3)

Update

Offices/Locations (1)

Update
  • Headquarters

    77 Digital Drive

    Suite 210

    Novato, CA 94949

    USA

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos